KALETRA

LOE ApproachingSM

lopinavir and ritonavir

NDAORALTABLETPriority Review
Approved
Oct 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

HIV Protease Inhibitors

Pharmacologic Class:

Protease Inhibitor

Clinical Trials (5)

NCT04138199N/ATerminated

A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation

Started Nov 2019
239 enrolled
HIV-1 Infection
NCT01662336N/ACompleted

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Started Jun 2012
173 enrolled
Human Immunodeficiency Virus Infection
NCT01328158N/ACompleted

Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection

Started Jun 2011
236 enrolled
Human Immunodeficiency Virus Infection
NCT01383005N/ACompleted

Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)

Started Jun 2011
97 enrolled
Human Immunodeficiency Virus Infection
NCT01068873Phase 4Terminated

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Started Apr 2010
1 enrolled
HIV Infections